213 related articles for article (PubMed ID: 34024854)
1. Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment.
Akutsu N; Sasaki S; Matsui T; Akashi H; Yonezawa K; Ishigami K; Tsujisaki M; Isshiki H; Yawata A; Yamaoka S; Ban T; Adachi T; Nakahara S; Takagi H; Nakachi K; Tanaka K; Hirano T; Yamamoto I; Kaneto H; Wagatsuma K; Numata Y; Nakase H
Intern Med; 2021 Nov; 60(21):3369-3376. PubMed ID: 34024854
[TBL] [Abstract][Full Text] [Related]
2. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E;
J Hepatol; 2020 Mar; 72(3):431-440. PubMed ID: 31655134
[TBL] [Abstract][Full Text] [Related]
3. Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis.
Zhang Y; Jiang X; Zhao Y; Xu Y
J Viral Hepat; 2021 Jan; 28(1):177-185. PubMed ID: 32961624
[TBL] [Abstract][Full Text] [Related]
4. Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients.
Singh AD; Maitra S; Singh N; Tyagi P; Ashraf A; Kumar R; Shalimar
Aliment Pharmacol Ther; 2020 Mar; 51(5):490-504. PubMed ID: 31943236
[TBL] [Abstract][Full Text] [Related]
5. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
Liu CH; Yang SS; Peng CY; Lin WT; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
J Viral Hepat; 2020 Jun; 27(6):568-575. PubMed ID: 31981264
[TBL] [Abstract][Full Text] [Related]
6. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
Gane E; de Ledinghen V; Dylla DE; Rizzardini G; Shiffman ML; Barclay ST; Calleja JL; Xue Z; Burroughs M; Gutierrez JA
J Viral Hepat; 2021 Nov; 28(11):1635-1642. PubMed ID: 34448313
[TBL] [Abstract][Full Text] [Related]
7. Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.
Cornberg M; Ahumada A; Aghemo A; Andreoni M; Bhagat A; Butrymowicz I; Carmiel M; Chodick G; Conway B; Song Y; Gasbarrini A; Hüppe D; Plaza FJ; Lampertico P; Alonso MLM; Myles L; Persico M; Ramji A; Sarrazin C; Villa E; Weil C; Otano JIU;
Adv Ther; 2022 Jul; 39(7):3146-3158. PubMed ID: 35543964
[TBL] [Abstract][Full Text] [Related]
8. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
Zuckerman E; Gutierrez JA; Dylla DE; de Ledinghen V; Muir AJ; Gschwantler M; Puoti M; Caruntu F; Slim J; Nevens F; Sigal S; Cohen S; Fredrick LM; Pires Dos Santos AG; Rodrigues L; Dillon JF
Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2544-2553.e6. PubMed ID: 32621971
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital.
Ruwayni AA; AlObary EE; Alyahya KM
Saudi Med J; 2024 Jan; 45(1):34-39. PubMed ID: 38220241
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
Back D; Belperio P; Bondin M; Negro F; Talal AH; Park C; Zhang Z; Pinsky B; Crown E; Mensa FJ; Marra F
J Viral Hepat; 2019 Aug; 26(8):951-960. PubMed ID: 30977945
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
Heo J; Kim YJ; Lee JW; Kim JH; Lim YS; Han KH; Jeong SH; Cho M; Yoon KT; Bae SH; Crown ED; Fredrick LM; Alami NN; Asatryan A; Kim DH; Paik SW; Lee YJ
Gut Liver; 2021 Nov; 15(6):895-903. PubMed ID: 34053916
[TBL] [Abstract][Full Text] [Related]
12. Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution.
Park YJ; Woo HY; Heo J; Park SG; Hong YM; Yoon KT; Kim DU; Kim GH; Kim HH; Song GA; Cho M
Gut Liver; 2021 May; 15(3):440-450. PubMed ID: 32839365
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
Chiu WN; Hung CH; Lu SN; Chen MY; Tung SY; Wei KL; Lu CK; Chen CH; Hu TH; Hu JH; Chen WM; Chang TS
J Viral Hepat; 2020 Sep; 27(9):866-872. PubMed ID: 32343472
[TBL] [Abstract][Full Text] [Related]
14. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan.
Liu CH; Liu CJ; Hung CC; Hsieh SM; Su TH; Sun HY; Tseng TC; Chen PJ; Chen DS; Kao JH
Liver Int; 2020 Apr; 40(4):758-768. PubMed ID: 31710759
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.
Yao BB; Fredrick LM; Schnell G; Kowdley KV; Kwo PY; Poordad F; Nguyen K; Lee SS; George C; Wong F; Gane E; Abergel A; Spearman CW; Nguyen T; Hung Le M; Pham TT; Mensa F; Asselah T
Liver Int; 2020 Oct; 40(10):2385-2393. PubMed ID: 32445613
[TBL] [Abstract][Full Text] [Related]
16. Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.
Poordad F; Felizarta F; Yao BB; Overcash JS; Hassanein T; Agarwal K; Gane E; Shaw D; Waters M; Krishnan P; Topp A; Burroughs M; Nevens F
Liver Int; 2022 Jun; 42(6):1278-1286. PubMed ID: 35220658
[TBL] [Abstract][Full Text] [Related]
17. Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).
Cornberg M; Stoehr A; Naumann U; Teuber G; Klinker H; Lutz T; Möller H; Hidde D; Lohmann K; Simon KG
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891520
[TBL] [Abstract][Full Text] [Related]
18. Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
Lampertico P; Mauss S; Persico M; Barclay ST; Marx S; Lohmann K; Bondin M; Zhang Z; Marra F; Belperio PS; Wedemeyer H; Flamm S
Adv Ther; 2020 Sep; 37(9):4033-4042. PubMed ID: 32754824
[TBL] [Abstract][Full Text] [Related]
19. Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.
Madsen LW; Christensen PB; Hansen JF; Røge BT; Holm DK; Dröse S; Øvrehus A
Viruses; 2022 Mar; 14(3):. PubMed ID: 35337021
[TBL] [Abstract][Full Text] [Related]
20. High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
Zamor PJ; Brown A; Dylla DE; Dillon JF; Luetkemeyer AF; Feld JJ; Mutimer D; Ghalib R; Crown E; Lovell SS; Hu Y; Moreno C; Nelson DR; Colombo M; Papatheodoridis G; Rockstroh JK; Skoien R; Lawitz E; Jacobson IM
Am J Gastroenterol; 2021 Sep; 116(9):1896-1904. PubMed ID: 34465693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
